ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancer

Peng, Kai-Cheng; Su, Jun-Wei; Xie, Zhi; Wang, Han-Min; Fang, Mei-Mei; Li, Wen-Feng; Chen, Yu-Qing; Guan, Xu-Hui; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Tu, Hai-Yan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji*广东省人民医院
Thoracic Cancer2022-6DOI: 10.1111/1759-7714.14429
5被引4阅读
引用收藏
分享

摘要

Background MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR-sensitive mutations and de novo MET amplifications still need to be explored. Methods A total of 54 patients from our hospital with non-small cell lung cancer harboring EGFR-sensitive mutations and/or de novo MET amplifications were included in this study. Survival rates were estimated by the Kaplan-Meier method with log-rank statistics. Lung cancer organoids (LCOs) were generated from patient-derived malignant pleural effusion to perform drug sensitivity assays. Results Fifty-four patients with the appropriate clinicopathological characteristics were enrolled. MET FISH was performed in 40 patients who were stratified accordingly into two groups: EGFR+/METamp- (n = 22) and EGFR+/METamp + (n = 18). Survival rates for EGFR+/METamp- and EGFR+/METamp + patients respectively, were as follows: the median progression-free survival (PFS) was 12.1 and 1.9 months (p<0.001); the median post-progression overall survival (pOS) was 25.6 and 11.6 months (p = 0.023); the median overall survival (OS) was 33.2 and 12.7 months (p = 0.013). Drug testing conducted in LCOs derived from malignant pleural effusion from EGFR+/METamp + patients showed that dual targeted therapy was more effective than TKI monotherapy. Conclusion EGFR+/METamp + patients treated with first-line TKI monotherapy had poor clinical outcomes. Dual targeted therapy showed potent anticancer activity in the LCO drug testing assay, suggesting that it is a promising first-line treatment for EGFR+/METamp + patients. Randomized controlled trials are needed to further validate these results.

学科与关键词

关键词
de novo MET amplificationEGFR-sensitive mutationnon-small cell lung cancerpatient-derived organoidtargeted therapy
相关
加载中…
  • Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
    Chen Hua Jun; Mok Tony S; Chen Zhi Hong; Guo Ai Lin; Zhang Xu Chao; Su Jian; Wu Yi Long*Pathology Oncology Research, 2009, 15(4): 651-658.被引 30
  • MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
    Peng, Lun-Xi; Jie, Guang-Ling; Li, An-Na; Liu, Si-Yang; Sun, Hao; Zheng, Mei-Mei; Zhou, Jia-Ying; Zhang, Jia-Tao; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Yang, Jin-Ji; Tu, Hai-Yan; Su, Jian; Yan, Hong-Hong; Wu, Yi-Long*Experimental Hematology & Oncology, 2021, 10(1): 52.被引 24
  • Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
    Gao, Xin; Wei, Xue-Wu; Zheng, Ming-Ying; Chen, Zhi-Hong; Zhang, Xu-Chao; Zhong, Wen-Zhao; Yang, Jin-Ji; Wu, Yi-Long; Zhou, Qing*Journal of Thoracic Disease, 2020, 12(10): 5822-+.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Thoracic Cancer
发表日期
2022-06
卷期
第 13 卷, 第 11 期
页码
1619-1630
DOI
10.1111/1759-7714.14429
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Key Lab System Project of Guangdong Science and Technology Department -Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; National Natural Science Foundation of China [81972164]; High-level Hospital Construction Project [DFJH201809]; Natural Science Foundation of Guangdong Province [2019A1515010931]

作者

  • P

    Peng, Kai-Cheng (第一作者)

    guangdong prov peoples hosp

  • S

    Su, Jun-Wei

    guangdong prov peoples hosp

查看全部 16 位作者收起作者
  • X

    Xie, Zhi

    guangdong prov peoples hosp

  • W

    Wang, Han-Min

    guangdong prov peoples hosp

  • F

    Fang, Mei-Mei

    guangdong prov peoples hosp

  • L

    Li, Wen-Feng

    guangdong prov peoples hosp

  • C

    Chen, Yu-Qing

    guangdong prov peoples hosp

  • G

    Guan, Xu-Hui

    guangdong prov peoples hosp

  • S

    Su, Jian

    guangdong prov peoples hosp

  • Y

    Yan, Hong-Hong

    guangdong prov peoples hosp

  • Z

    Zhang, Xu-Chao

    guangdong prov peoples hosp

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp

  • Z

    Zhou, Qing

    guangdong prov peoples hosp

  • C

    Chen, Hua-Jun

    guangdong prov peoples hosp

  • W

    Wu, Yi-Long

    guangdong prov peoples hosp

  • Y

    Yang, Jin-Ji (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417